Clinical trials: Dementia, Mild
Alzheimer Disease
A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD).
- Trial name
- NCT06881836
- Testing
- ONO-2020
- Where
- 80 sites in United States, Japan
- Volunteers
- 260 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Alzheimer's Disease, Mild Cognitive Impairment
Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)
The primary objective of this protocol is to determine if brain amyloid imaged with florbetapir F 18 (18F-AV-45) PET scans is predictive of progressive cognitive impairment during the subsequent 36 months for groups of: normal…
- Trial name
- NCT00857506
- Testing
- florbetapir F 18
- Where
- 8 sites in United States
- Volunteers
- 152 people
- Sponsor
- Avid Radiopharmaceuticals
Lewy Body Dementia
A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
A randomized placebo-controlled trial to evaluate the safety and efficacy of three doses of study drug LY3154207 treated for 12 weeks in participants with mild-to-moderate dementia associated with LBD (PDD or DLB).
- Trial name
- PRESENCE (NCT03305809)
- Testing
- LY3154207
- Where
- 77 sites in United States, Canada and 1 more
- Volunteers
- 344 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease
The study involves repeated doses of LY3303560 given by infusion for 49 weeks. The study will examine how safe repeated doses of LY3303560 are, whether they cause side effects in participants with mild cognitive impairment or…
- Trial name
- NCT03019536
- Testing
- LY3303560 - IV, Florbetapir F 18, Flortaucipir F18
- Where
- 11 sites in United States, Japan and 1 more
- Volunteers
- 22 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease
This 4 arm study will assess the efficacy and safety of RO5313534 (MEM3454) versus placebo added to donepezil, in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00884507
- Testing
- RO5313534
- Where
- 67 sites in United States, Argentina and 11 more
- Volunteers
- 389 people
- Sponsor
- Hoffmann-La Roche
Alzheimer Dementia
Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease
STUDY OBJECTIVES Primary: To assess the safety and tolerability of ischemia-tolerant allogeneic human mesenchymal stem cells (hMSCs) manufactured by Stemedica versus placebo administered intravenously to subjects with mild to…
- Trial name
- NCT02833792
- Testing
- Human Mesenchymal Stem Cells and Lactated Riunger's Solution
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Stemedica Cell Technologies, Inc.
Neurocognitive Disorders, Mild, Cognitive Impairment, Mild
Effects of Personalized Digital Reminiscence Therapy on Patients With Neurocognitive Disorders
This study aims to observe the effects of daily personalized digital reminiscence sessions, conducted with the help of a digital conversational agent, and to determine whether these sessions lead to improvements in symptoms such…
- Conditions
- Neurocognitive Disorders, Mild, Cognitive Impairment, Mild, Depression Mild, Apathy
- Trial name
- NCT07237009
- Where
- 5 sites in France
- Volunteers
- 80 people
- Sponsor
- KompanionCare SAS
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of QLH2405 injection in healthy participants and participants with mild cognitive impairment (MCI) due to…
- Trial name
- NCT07489599
- Testing
- QLH2405
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Alzheimer's Disease, Lewy Body Dementia
Pulsed Electromagnetic Field Treatment With Dementia Patients
An open label pilot study in mild to moderate AD/ADRD patients to assess the effects of treatment with ECHS AD/ADRD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices.
- Conditions
- Alzheimer's Disease, Lewy Body Dementia, Vascular Dementia
- Trial name
- NCT06862557
- Testing
- ECHS AD Device
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Herrick Medical LLC
Dementia, Mild Cognitive Impairment
HOme-based Brain Monitoring With a GARment-EEG to Study Cognitive Decline in the Aging Population
This study will investigate the validity of the HOGAR EEG/PSG monitoring kit designed by Bitbrain as a tool for characterizing and assessing cognitive function in older adults, as well as for detecting and predicting cognitive…
- Conditions
- Dementia, Mild Cognitive Impairment, Dementia Alzheimers, Dementia, Mixed
- Trial name
- Hogar (NCT06993207)
- Testing
- Home Lab
- Where
- Spain
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Bitbrain
Alzheimer's Disease
SB-742457 And Donepezil In Alzheimer's Disease
The purpose of this study is to find out if SB-742457 is a safe treatment and what effects it has on the symptoms of mild to moderate Alzheimer's Disease.
- Trial name
- NCT00348192
- Testing
- SB-742457, donepezil
- Where
- 26 sites in Austria, Bulgaria and 6 more
- Volunteers
- 200 people
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease Dementia
Alzheimer's Disease THErapy With NEuroaid II
ATHENE II is a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial designed to evaluate the efficacy and safety of MLC901 in subjects with mild to moderate Alzheimer's disease, as well as its effects…
- Trial name
- ATHENE II (NCT07191028)
- Testing
- MLC 901
- Where
- Singapore
- Volunteers
- 350 people
- Sponsor
- Moleac Pte Ltd.
Alzheimer's Disease
A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease
This is a study to evaluate the safety, tolerability and blood levels of PF-03654746 in subjects will mild to moderate Alzheimer's disease.
- Trial name
- NCT01028911
- Testing
- PF-03654746
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Pfizer
Alzheimer's Disease
Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
This is an open-label, longitudinal observational study evaluating the imaging characteristics of the tau positron-emission tomography (PET) radioligand [18F] Genentech Tau Probe 1 (GTP1) in the brain of participants with…
- Trial name
- NCT02640092
- Testing
- [18F]GTP1
- Where
- 16 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Alzheimer Disease
A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD
The study will evaluate the effect of LY3002813 on brain scans. The study will evaluate the safety of LY3002813 by looking at adverse events (side effects). The study will also look at the effect the body has on LY3002813.
- Trial name
- NCT02624778
- Testing
- LY3002813
- Where
- 9 sites in United States, Japan
- Volunteers
- 61 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
European Study of HF0220 in Mild to Moderate Alzheimer's Disease Patients
The purpose of this Phase II study is to evaluate the safety and tolerability of HF 0220 in patients with Alzheimer's disease compared to placebo (inactive substance).
- Trial name
- NCT00357357
- Testing
- HF0220
- Where
- 10 sites in India, Sweden and 1 more
- Volunteers
- 40 people
- Sponsor
- Hunter-Fleming Ltd
Alzheimer's Disease
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
This study is designed to evaluate the safety, tolerability and pharmacokinetics of multiple doses of ABT-957 in subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT02220738
- Testing
- ABT-957
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- AbbVie
Irregular Sleep-Wake Rhythm Disorder
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
This study will be conducted to determine the dose response of lemborexant (LEM) on the change from baseline in actigraphy-derived sleep-related parameters, wake-related parameters, and circadian-rhythm related parameters.
- Trial name
- NCT03001557
- Testing
- Lemborexant 2.5 mg, Lemborexant 5 mg, Lemborexant 10 mg
- Where
- 48 sites in United States, Japan and 1 more
- Volunteers
- 63 people
- Sponsor
- Eisai Inc.
Mild to Moderate Alzheimer's Disease
Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease
This is a Phase IIa study assessing the safety, tolerability and preliminary efficacy of ORY-2001 in mild to moderate Alzheimer's Disease patients.
- Trial name
- ETHERAL-US (NCT03867253)
- Testing
- ORY-2001 Low dose, ORY-2001 High dose
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Oryzon Genomics S.A.
Alzheimer's Disease
2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)
This is an open-label extension study in patients with mild Alzheimer's disease who have completed participation in the azeliragon Phase 3 (STEADFAST) trial. Patients will receive azeliragon 5 mg/day for up to 2 years.
- Trial name
- NCT02916056
- Testing
- Azeliragon 5mg
- Where
- 71 sites in United States, Canada
- Volunteers
- 297 people
- Sponsor
- vTv Therapeutics